Pluto Bioinformatics

GSE98212: A third generation therapeutic vaccine for human visceral leishmaniasis and post kala azar dermal leishmaniasis: first-in-human trial of ChAd63-KH

Bulk RNA sequencing

Whole blood transcriptomic profiling indicated that CHAd63-KH induced innate immune responses characterized by an interferon signature and the presence of activated dendritic cells. SOURCE: Paul Kaye University of York